Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial)
Status:
Completed
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
Type 2 diabetes mellitus is a chronic metabolic disorder characterized by progressive
deterioration in the function of the pancreatic beta-cells, which are the cells that produce
and secrete insulin (the hormone primarily responsible for the handling of glucose in the
body). The investigators propose a randomized controlled trial to determine whether
intermittent intensive insulin therapy is an effective therapeutic strategy that can preserve
pancreatic beta-cell function and maintain glycemic control early in the course of type 2
diabetes.